Barclays Boosts Becton, Dickinson and Company (NYSE:BDX) Price Target to $312.00

Becton, Dickinson and Company (NYSE:BDX) had its price target raised by Barclays from $305.00 to $312.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has an “overweight” rating on the medical instruments supplier’s stock. Barclays‘s target price points to a potential upside of 31.57% from the stock’s previous close.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $237.14 on Monday. The company has a market capitalization of $68.54 billion, a price-to-earnings ratio of 52.23, a PEG ratio of 1.92 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41. The company has a 50-day simple moving average of $238.27 and a 200 day simple moving average of $239.97. Becton, Dickinson and Company has a 52 week low of $229.40 and a 52 week high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, topping the consensus estimate of $2.97 by $0.20. The business had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. Becton, Dickinson and Company’s revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.86 EPS. On average, sell-side analysts predict that Becton, Dickinson and Company will post 13.04 earnings per share for the current year.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the sale, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the sale, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the sale, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The disclosure for this sale can be found here. Insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Becton, Dickinson and Company

A number of institutional investors have recently added to or reduced their stakes in the stock. NorthRock Partners LLC acquired a new position in Becton, Dickinson and Company during the 1st quarter worth approximately $205,000. Sei Investments Co. increased its position in Becton, Dickinson and Company by 14.3% during the 1st quarter. Sei Investments Co. now owns 207,387 shares of the medical instruments supplier’s stock worth $51,312,000 after purchasing an additional 25,977 shares in the last quarter. Reynders McVeigh Capital Management LLC increased its position in Becton, Dickinson and Company by 4.6% during the 1st quarter. Reynders McVeigh Capital Management LLC now owns 118,470 shares of the medical instruments supplier’s stock worth $29,313,000 after purchasing an additional 5,208 shares in the last quarter. Heartland Advisors Inc. increased its position in Becton, Dickinson and Company by 20.4% during the 1st quarter. Heartland Advisors Inc. now owns 17,605 shares of the medical instruments supplier’s stock worth $4,356,000 after purchasing an additional 2,981 shares in the last quarter. Finally, Forsta AP Fonden increased its position in Becton, Dickinson and Company by 7.3% in the 1st quarter. Forsta AP Fonden now owns 57,000 shares of the medical instruments supplier’s stock valued at $14,105,000 after acquiring an additional 3,900 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.